Jason Ryan
CIK 1585017 · Executive Chairman · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FMI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE KENDALL SQUARE, SUITE B3501
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WGS | Director | 118,764 | $62.19 | $7.39M | $0 | 1 | 2026-06-23 |
| GeneDx Holdings Corp. (WGSWW) Delisted | Director | 135,473 | $0.00 | $27 | -$8.15M | 11 | 2025-08-27 |
| Singular Genomics Systems, Inc. (OMIC) Delisted | Director | — | $20.01 | — | $0 | 3 | 2024-05-31 |
| SomaLogic, Inc. (SLGCW) Delisted | Director | — | $0.09 | — | $0 | 1 | 2023-06-12 |
| GeneDx Holdings Corp. (SMFRW) Delisted | Executive Chairman | 263,358 | $0.02 | $6.3K | -$20.4K | 6 | 2023-01-04 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | See Remarks | — | $11.19 | — | $0 | 2 | 2020-02-12 |
| Foundation Medicine, Inc. (FMI) Delisted | Chief Financial Officer | 49,170 | — | — | -$10.37M | 38 | 2018-07-05 |
Recent Filings · Page 4 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-04-18 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −3,449 | -$256.3K | EDGAR |
| 2018-04-05 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −1 | -$72 | EDGAR |
| 2018-04-03 | Foundation Medicine, Inc. (FMI) Delisted | Mixed | +6,793 | $550.4K | EDGAR |
| 2018-03-19 | Foundation Medicine, Inc. (FMI) Delisted | Mixed | — | -$729.5K | EDGAR |
| 2018-02-20 | Foundation Medicine, Inc. (FMI) Delisted | Mixed | — | -$568.5K | EDGAR |
| 2018-01-18 | Foundation Medicine, Inc. (FMI) Delisted | Mixed | −1,035 | -$761.6K | EDGAR |
| 2018-01-03 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −2,336 | -$149.5K | EDGAR |
| 2017-12-07 | Foundation Medicine, Inc. (FMI) Delisted | Mixed | — | -$1.20M | EDGAR |
| 2017-11-06 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −9,731 | -$486.6K | EDGAR |
| 2017-10-16 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −1,152 | -$51.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.